MMWR Morb Mortal Wkly Rep. 1999 Feb 26;48(7):137-40.
Products containing gamma-butyrolactone (GBL) are marketed for many claimed purposes, including to induce sleep, release growth hormone, enhance sexual activity and athletic performance, relieve depression, and prolong life. GBL is converted by the body into gamma-hydroxybutyrate (GHB), a drug banned outside of clinical trials approved by the Food and Drug Administration (FDA). Recognized manifestations of GHB toxicity include bradycardia, hypothermia, central nervous system depression, and uncontrolled movements. This report describes seven cases of GBL toxicity involving the product "Revivarant," which is labeled as containing 1.82 g of GBL per fluid ounce, reported from two hospital emergency departments (EDs) in Minnesota during October-December 1998 and summarizes an additional 34 cases of GBL toxicity reported to poison centers in New Mexico and Texas during October 1998-January 1999.
含有γ-丁内酯（GBL）的产品因多种声称的用途而被销售，包括诱导睡眠、释放生长激素、增强性活动和运动表现、缓解抑郁以及延长寿命。GBL在体内会转化为γ-羟基丁酸（GHB），这是一种在食品药品监督管理局（FDA）批准的临床试验之外被禁用的药物。GHB毒性的公认表现包括心动过缓、体温过低、中枢神经系统抑制和不受控制的运动。本报告描述了1998年10月至12月期间明尼苏达州两家医院急诊科报告的7例涉及“Revivarant”产品的GBL毒性病例，该产品标签显示每液量盎司含有1.82克GBL，并总结了1998年10月至1999年1月期间新墨西哥州和得克萨斯州中毒控制中心报告的另外34例GBL毒性病例。
